Leerink lowered the firm’s price target on Ardent Health (ARDT) to $23 from $24 and keeps an Outperform rating on the shares. The firm believes Q2 results brought forth many consistent themes anchored to above average demand, solid rate, disciplined cost controls and advancement of the OP agenda. Ardent continues to perform well against targets, carries lots of growth and margin gains and continues to under-earn its potential. Management strikes a confident tone around the development pipeline, has lots of capacity to grow inorganically and has outpaced the sector on admit growth, Leerink adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $20 from $24 at KeyBanc
- Sell Rating for Ardent Health Partners Due to Anticipated State Directed Payment Cuts and Profitability Challenges
- Ardent Health Reports Strong Q2 2025 Results
- Ardent Health reports Q2 EPS 52c, consensus 32c
- Ardent Health sees FY25 EPS $1.73-$2.01, consensus $2.01